Laura Fairneny

Laura Fairneny is a patent litigation attorney with a practice focused on complex intellectual property disputes, particularly within the life sciences sector. She is currently with Patterson Belknap Webb & Tyler LLP, having previously practiced at Quinn Emanuel Urquhart & Sullivan, LLP since 2009.

Fairneny's practice areas primarily encompass pharmaceutical, biotechnology, and medical device patent litigation. Her experience includes Hatch-Waxman litigation, as evidenced by her representation of clients like Allergan, Forest Laboratories, and Vifor in cases involving drug therapies for gastrointestinal disorders, Alzheimer's disease, and hyperkalemia, respectively, where she secured consent judgments with injunctions. She has also handled patent disputes concerning surgical products and has experience in International Trade Commission (ITC) investigations. While the tracked case shows her appearing on the plaintiff side, her prior firm profile indicates she handles both offensive and defensive matters.

A notable tracked case where Fairneny is involved is Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc., where she appeared pro hac vice for the plaintiff, Veloxis Pharmaceuticals, Inc., in a patent dispute in the U.S. District Court for the District of Delaware. Her broader experience includes securing a jury verdict of infringement and damages for Tyco Healthcare Group LP and winning summary judgment of non-infringement for Covidien in patent infringement litigation. She also obtained a "no violation" finding in an ITC investigation for Cablevision Systems Corp. and won an arbitration award for a non-profit organization against a pharmaceutical company involving mRNA drug therapies.

Fairneny earned her J.D. from the University of Virginia School of Law in 2008 and holds a B.A. from the University of Virginia (2005). She is admitted to practice in the State Bar of New York and the Bar of the Commonwealth of Massachusetts.